Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: Long-term follow-up

Amanda Psyrri, M. Kwong, S. DiStasio, L. Lekakis, M. Kassar, C. Sasaki, L. D. Wilson, B. G. Haffty, Y. H. Son, D. A. Ross, P. M. Weinberger, G. G. Chung, D. Zelterman, B. A. Burtness, D. L. Cooper

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Purpose: The poor functional outcome in patients with advanced head and neck squamous cell carcinoma (HNSCC) with surgery and radiation has led to alternative approaches to advanced disease. We conducted a phase II study of induction chemotherapy followed by concurrent chemoradiotherapy for organ preservation in patients with advanced resectable and unresectable (nasopharyngeal) tumors. Patients and Methods: Forty-two patients with stage III to IV resectable HNSCC and nasopharyngeal tumors received induction chemotherapy with two courses of cisplatin (20 mg/m2/d continuous infusion [CI]), fluorouracil (800 mg/m2/d CI), and leucovorin (500 mg/m2/d CI; PFL) for 4 days followed by concurrent therapy with cisplatin (100 mg/m2/d on days 1 and 22) and approximately 70 Gy of external-beam radiotherapy. Results: Response to induction chemotherapy included partial response rate of 52% and complete response rate of 24%. The most common grade 3 or 4 toxicity was neutropenia (59%). After cisplatin chemoradiotherapy the complete response rate was 67%. Toxicities of cisplatin chemoradiotherapy consisted of grade 3 or 4 mucositis (79%) and neutropenia (51%). At a median follow-up of 71.5 months, 43% of the patients are still alive and disease-free. The 5-year progression-free survival (PFS) rate was 60%, and the 2- and 5-year overall survival (OS) rates were 67% and 52%, respectively. Three patients died of second primaries. Late complications of treatment included xerostomia and hoarseness. One patient had persistent dysphagia and required laser epiglotectomy 108 months after treatment. Conclusion: Induction chemotherapy with PFL followed by concurrent cisplatin chemoradiotherapy is well tolerated and results in a good likelihood of organ preservation and excellent PFS and OS.

Original languageEnglish (US)
Pages (from-to)3061-3069
Number of pages9
JournalJournal of Clinical Oncology
Volume22
Issue number15
DOIs
StatePublished - Dec 1 2004

Fingerprint

Organ Preservation
Induction Chemotherapy
Leucovorin
Chemoradiotherapy
Head and Neck Neoplasms
Fluorouracil
Cisplatin
Neutropenia
Disease-Free Survival
Survival Rate
Xerostomia
Hoarseness
Mucositis
Deglutition Disorders
Neoplasms
Lasers
Radiotherapy
Therapeutics
Radiation
Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer : Long-term follow-up. / Psyrri, Amanda; Kwong, M.; DiStasio, S.; Lekakis, L.; Kassar, M.; Sasaki, C.; Wilson, L. D.; Haffty, B. G.; Son, Y. H.; Ross, D. A.; Weinberger, P. M.; Chung, G. G.; Zelterman, D.; Burtness, B. A.; Cooper, D. L.

In: Journal of Clinical Oncology, Vol. 22, No. 15, 01.12.2004, p. 3061-3069.

Research output: Contribution to journalArticle

Psyrri, A, Kwong, M, DiStasio, S, Lekakis, L, Kassar, M, Sasaki, C, Wilson, LD, Haffty, BG, Son, YH, Ross, DA, Weinberger, PM, Chung, GG, Zelterman, D, Burtness, BA & Cooper, DL 2004, 'Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: Long-term follow-up', Journal of Clinical Oncology, vol. 22, no. 15, pp. 3061-3069. https://doi.org/10.1200/JCO.2004.01.108
Psyrri, Amanda ; Kwong, M. ; DiStasio, S. ; Lekakis, L. ; Kassar, M. ; Sasaki, C. ; Wilson, L. D. ; Haffty, B. G. ; Son, Y. H. ; Ross, D. A. ; Weinberger, P. M. ; Chung, G. G. ; Zelterman, D. ; Burtness, B. A. ; Cooper, D. L. / Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer : Long-term follow-up. In: Journal of Clinical Oncology. 2004 ; Vol. 22, No. 15. pp. 3061-3069.
@article{bb52dc219d9f483fa44995ffb3c84f37,
title = "Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: Long-term follow-up",
abstract = "Purpose: The poor functional outcome in patients with advanced head and neck squamous cell carcinoma (HNSCC) with surgery and radiation has led to alternative approaches to advanced disease. We conducted a phase II study of induction chemotherapy followed by concurrent chemoradiotherapy for organ preservation in patients with advanced resectable and unresectable (nasopharyngeal) tumors. Patients and Methods: Forty-two patients with stage III to IV resectable HNSCC and nasopharyngeal tumors received induction chemotherapy with two courses of cisplatin (20 mg/m2/d continuous infusion [CI]), fluorouracil (800 mg/m2/d CI), and leucovorin (500 mg/m2/d CI; PFL) for 4 days followed by concurrent therapy with cisplatin (100 mg/m2/d on days 1 and 22) and approximately 70 Gy of external-beam radiotherapy. Results: Response to induction chemotherapy included partial response rate of 52{\%} and complete response rate of 24{\%}. The most common grade 3 or 4 toxicity was neutropenia (59{\%}). After cisplatin chemoradiotherapy the complete response rate was 67{\%}. Toxicities of cisplatin chemoradiotherapy consisted of grade 3 or 4 mucositis (79{\%}) and neutropenia (51{\%}). At a median follow-up of 71.5 months, 43{\%} of the patients are still alive and disease-free. The 5-year progression-free survival (PFS) rate was 60{\%}, and the 2- and 5-year overall survival (OS) rates were 67{\%} and 52{\%}, respectively. Three patients died of second primaries. Late complications of treatment included xerostomia and hoarseness. One patient had persistent dysphagia and required laser epiglotectomy 108 months after treatment. Conclusion: Induction chemotherapy with PFL followed by concurrent cisplatin chemoradiotherapy is well tolerated and results in a good likelihood of organ preservation and excellent PFS and OS.",
author = "Amanda Psyrri and M. Kwong and S. DiStasio and L. Lekakis and M. Kassar and C. Sasaki and Wilson, {L. D.} and Haffty, {B. G.} and Son, {Y. H.} and Ross, {D. A.} and Weinberger, {P. M.} and Chung, {G. G.} and D. Zelterman and Burtness, {B. A.} and Cooper, {D. L.}",
year = "2004",
month = "12",
day = "1",
doi = "10.1200/JCO.2004.01.108",
language = "English (US)",
volume = "22",
pages = "3061--3069",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "15",

}

TY - JOUR

T1 - Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer

T2 - Long-term follow-up

AU - Psyrri, Amanda

AU - Kwong, M.

AU - DiStasio, S.

AU - Lekakis, L.

AU - Kassar, M.

AU - Sasaki, C.

AU - Wilson, L. D.

AU - Haffty, B. G.

AU - Son, Y. H.

AU - Ross, D. A.

AU - Weinberger, P. M.

AU - Chung, G. G.

AU - Zelterman, D.

AU - Burtness, B. A.

AU - Cooper, D. L.

PY - 2004/12/1

Y1 - 2004/12/1

N2 - Purpose: The poor functional outcome in patients with advanced head and neck squamous cell carcinoma (HNSCC) with surgery and radiation has led to alternative approaches to advanced disease. We conducted a phase II study of induction chemotherapy followed by concurrent chemoradiotherapy for organ preservation in patients with advanced resectable and unresectable (nasopharyngeal) tumors. Patients and Methods: Forty-two patients with stage III to IV resectable HNSCC and nasopharyngeal tumors received induction chemotherapy with two courses of cisplatin (20 mg/m2/d continuous infusion [CI]), fluorouracil (800 mg/m2/d CI), and leucovorin (500 mg/m2/d CI; PFL) for 4 days followed by concurrent therapy with cisplatin (100 mg/m2/d on days 1 and 22) and approximately 70 Gy of external-beam radiotherapy. Results: Response to induction chemotherapy included partial response rate of 52% and complete response rate of 24%. The most common grade 3 or 4 toxicity was neutropenia (59%). After cisplatin chemoradiotherapy the complete response rate was 67%. Toxicities of cisplatin chemoradiotherapy consisted of grade 3 or 4 mucositis (79%) and neutropenia (51%). At a median follow-up of 71.5 months, 43% of the patients are still alive and disease-free. The 5-year progression-free survival (PFS) rate was 60%, and the 2- and 5-year overall survival (OS) rates were 67% and 52%, respectively. Three patients died of second primaries. Late complications of treatment included xerostomia and hoarseness. One patient had persistent dysphagia and required laser epiglotectomy 108 months after treatment. Conclusion: Induction chemotherapy with PFL followed by concurrent cisplatin chemoradiotherapy is well tolerated and results in a good likelihood of organ preservation and excellent PFS and OS.

AB - Purpose: The poor functional outcome in patients with advanced head and neck squamous cell carcinoma (HNSCC) with surgery and radiation has led to alternative approaches to advanced disease. We conducted a phase II study of induction chemotherapy followed by concurrent chemoradiotherapy for organ preservation in patients with advanced resectable and unresectable (nasopharyngeal) tumors. Patients and Methods: Forty-two patients with stage III to IV resectable HNSCC and nasopharyngeal tumors received induction chemotherapy with two courses of cisplatin (20 mg/m2/d continuous infusion [CI]), fluorouracil (800 mg/m2/d CI), and leucovorin (500 mg/m2/d CI; PFL) for 4 days followed by concurrent therapy with cisplatin (100 mg/m2/d on days 1 and 22) and approximately 70 Gy of external-beam radiotherapy. Results: Response to induction chemotherapy included partial response rate of 52% and complete response rate of 24%. The most common grade 3 or 4 toxicity was neutropenia (59%). After cisplatin chemoradiotherapy the complete response rate was 67%. Toxicities of cisplatin chemoradiotherapy consisted of grade 3 or 4 mucositis (79%) and neutropenia (51%). At a median follow-up of 71.5 months, 43% of the patients are still alive and disease-free. The 5-year progression-free survival (PFS) rate was 60%, and the 2- and 5-year overall survival (OS) rates were 67% and 52%, respectively. Three patients died of second primaries. Late complications of treatment included xerostomia and hoarseness. One patient had persistent dysphagia and required laser epiglotectomy 108 months after treatment. Conclusion: Induction chemotherapy with PFL followed by concurrent cisplatin chemoradiotherapy is well tolerated and results in a good likelihood of organ preservation and excellent PFS and OS.

UR - http://www.scopus.com/inward/record.url?scp=4143088353&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4143088353&partnerID=8YFLogxK

U2 - 10.1200/JCO.2004.01.108

DO - 10.1200/JCO.2004.01.108

M3 - Article

C2 - 15284256

AN - SCOPUS:4143088353

VL - 22

SP - 3061

EP - 3069

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 15

ER -